Pacira BioSciences (PCRX) EBIT: 2010-2025
Historic EBIT for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to $6.4 million.
- Pacira BioSciences' EBIT rose 104.56% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.6 million, marking a year-over-year increase of 164.02%. This contributed to the annual value of -$73.4 million for FY2024, which is 183.69% down from last year.
- Per Pacira BioSciences' latest filing, its EBIT stood at $6.4 million for Q3 2025, which was down 25.14% from $8.5 million recorded in Q2 2025.
- In the past 5 years, Pacira BioSciences' EBIT ranged from a high of $39.9 million in Q2 2023 and a low of -$139.5 million during Q3 2024.
- Over the past 3 years, Pacira BioSciences' median EBIT value was $13.2 million (recorded in 2024), while the average stood at $2.8 million.
- In the last 5 years, Pacira BioSciences' EBIT skyrocketed by 587.52% in 2021 and then tumbled by 887.35% in 2024.
- Quarterly analysis of 5 years shows Pacira BioSciences' EBIT stood at $4.2 million in 2021, then crashed by 334.93% to -$9.9 million in 2022, then skyrocketed by 435.27% to $33.2 million in 2023, then dropped by 25.52% to $24.7 million in 2024, then surged by 104.56% to $6.4 million in 2025.
- Its EBIT stands at $6.4 million for Q3 2025, versus $8.5 million for Q2 2025 and $2.0 million for Q1 2025.